Antitumor activity of TZT-1027, a novel dolastatin 10 derivative. - Wikidata - wikimedia - TriplyDB

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

http://www.wikidata.org/entity/Q48773255

about

Bioactive Compounds Isolated from Microalgae in Chronic Inflammation and Cancer Marine Mollusk-Derived Agents with Antiproliferative Activity as Promising Anticancer Agents to Overcome Chemotherapy Resistance.Cyanobacteria: an emerging source for drug discovery.The expanding role of marine microbes in pharmaceutical development.Bioactive natural products from Papua New Guinea marine sponges.Interactions of antimitotic peptides and depsipeptides with tubulin.Culturable rare Actinomycetes: diversity, isolation and marine natural product discovery.First natural analogs of the cytotoxic thiodepsipeptide thiocoraline A from a marine Verrucosispora sp.Peptides with anticancer use or potential.The novel microtubule-interfering agent TZT-1027 enhances the anticancer effect of radiation in vitro and in vivo Novel Azetidine-Containing TZT-1027 Analogues as Antitumor Agents.Novel drugs from marine microorganisms.Systems biology of cyanobacterial secondary metabolite production and its role in drug discovery.Early investigational tubulin inhibitors as novel cancer therapeutics.Bombesin marine toxin conjugates inhibit the growth of lung cancer cells.Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB.Antivascular effects of TZT-1027 (Soblidotin) on murine Colon26 adenocarcinoma.Reference profiling of the genomic response induced by an antimicrotubule agent, TZT-1027 (Soblidotin), in vitro.Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer.Antineoplastic agents. 592. Highly effective cancer cell growth inhibitory structural modifications of dolastatin 10.Therapeutic potential of SGN-CD19B, a PBD-based anti-CD19 drug conjugate, for treatment of B-cell malignancies.Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial growth factor-secreting human lung cancer in vivo.Vascular disrupting agents.Characterization of the interaction of TZT-1027, a potent antitumor agent, with tubulin.TZT-1027, an antimicrotubule agent, attacks tumor vasculature and induces tumor cell death.Epothilones and new analogues of the microtubule modulators in taxane-resistant disease

P2860

Q26782065-F582F41F-94D8-4DA8-850F-28E968EDD554 Q33834080-D096E884-E08D-4AC0-8828-0EECF9CCC2C7 Q33863512-83F00029-3B35-4776-BA76-DB83CA575656 Q34362843-87A44D2B-2217-488F-816D-A6F75955E235 Q34451799-72797901-BF96-4308-BB16-E092548C2763 Q34972878-DDD1A8B1-0261-48BE-AAB2-1F22EFB87D40 Q34993999-222932F0-1AD0-4255-BF3D-0DE1DF701FAC Q35162970-EC7026F0-6D0A-41B9-8D1A-4DF45F30CAB3 Q35167010-1947134F-7681-4C77-83F6-0A1F42E20F12 Q36609596-9825715E-1033-4382-8FA9-85182DE29E70 Q36941448-7DB79457-F8A2-4EDB-ABB5-F05661EBD8D0 Q37877701-B5AF8503-CE31-4B6B-817F-5C43B1EDBC53 Q38088802-CB20462B-9464-4AA4-9045-4F24C42CFA49 Q38836161-EB1CAEE9-0EC6-45C5-91A4-C4DC4A7ED7B4 Q40003185-CE830B08-EF7A-4199-A0BD-32FC61B2E285 Q40125459-9E04D778-09B2-4936-A8AB-07ADA8184715 Q40227957-660075D3-6C5A-440A-920C-E7421631709E Q40301795-08BB3CEF-A675-486B-A581-BA2A135A39D2 Q40428919-699883CC-D2DA-4315-BEAD-C7B76B26E586 Q42761153-3152BCE9-636F-42ED-B278-E3A56F76CFE9 Q43525091-44370CD6-3867-4311-8931-3828A0981E31 Q44580396-0E415A17-7ACE-4AC0-AC1B-2AF402BB08A4 Q52573049-5C6528EF-1527-4A6E-BF74-2F6480407E2F Q54974194-A463D9E3-5922-4645-B3B2-F3E45F2F4CD1 Q55040537-557CB624-B8FB-4CC7-9C55-21418C500881 Q57244875-4B10659E-8661-41D0-AD5F-14D1D70B12B4

P2860

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

http://www.wikidata.org/entity/Q48773255

description

1997 nî lūn-bûn

@nan

1997年の論文

@ja

1997年学术文章

@wuu

1997年学术文章

@zh-cn

1997年学术文章

@zh-hans

1997年学术文章

@zh-my

1997年学术文章

@zh-sg

1997年學術文章

@yue

1997年學術文章

@zh

1997年學術文章

@zh-hant

name

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

@en

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

@nl

type

label

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

@en

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

@nl

prefLabel

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

@en

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

@nl

P1433

Q48773255-37EC54A7-36C8-442B-ADDA-6A46D48BEC8A

P1476

Q48773255-7FF30E72-5FB4-4417-AEA5-C6F31B8B9759

P2093

Q48773255-0DD20180-6634-4E83-B3E2-8888A6DCDB75

Q48773255-137DD0B7-F0E5-4D25-A4B5-DC861480A9B2

Q48773255-683D7FA1-CDEC-4FCC-9DD7-E9D3418CBDBA

Q48773255-7B9AF5F7-3973-48DF-B938-6209BD7BCDFB

Q48773255-8569B2E9-0077-48FB-9F8F-44476962E984

Q48773255-B968569C-ECA0-4E94-A858-93017CB8A77D

Q48773255-C89C980B-2A92-4A60-B821-F740E2E8E255

Q48773255-C93E3B68-6D85-4982-BC68-5BD3F191EB95

Q48773255-D211DAC7-7FC4-4ABA-8734-9EA343BC3F23

Q48773255-D6BD2ED4-5EAE-4CF8-BEFF-6ADA30D7BE25

P2860

Q48773255-17F60EDE-7D8F-4351-A814-6F0DAFDA86DA

Q48773255-2D6F8C0E-55AA-4204-8245-F7135A8FF7F4

Q48773255-2FBE864E-7C5B-4C4B-80E0-0372F9217555

Q48773255-3DA35040-494A-4BF4-BA85-400612483B81

Q48773255-475F2B83-533B-4803-B031-94201AAC1462

Q48773255-4A1F5D9E-EC81-4F43-A3EF-E79621DEC6C8

Q48773255-4A2E6B76-DB3C-41FE-815E-A8D6A7F2720A

Q48773255-4CCDCBBB-44A4-4C49-A2C4-EEC65D587EE7

Q48773255-51039069-70AF-4C63-85FE-20676B119BF7

Q48773255-651F6C9B-6E48-4701-A3C8-79BD07CB7B54

P304

Q48773255-2E310F3F-E230-4F33-B745-F1436E6CB95C

P31

Q48773255-F6C84981-2384-41D9-9C56-F370B6F29F87

P356

Q48773255-60ED36C9-221D-4ABC-89EB-18E6278EDDC4

P433

Q48773255-228DA846-38C8-452E-8BA3-935546752DE4

P478

Q48773255-62CA7C69-FF61-4587-A4A1-EB7A68529FFD

P577

Q48773255-B321C214-2369-4322-8444-90CE7A2BB96C

P5875

Q48773255-F3D94E5A-8012-457F-A489-9CA4317D5899

P698

Q48773255-6DFABFCF-DB5F-4B79-9FB4-0C6050822267

P932

Q48773255-47977F59-7C37-4D16-B3E3-D7B5D52AA590

P356

J.1349-7006.1997.TB00383.X

P1433

Japanese Journal of Cancer Research

P1476

Antitumor activity of TZT-1027, a novel dolastatin 10 derivative.

@en

P2093

H Asano

http://www.w3.org/2001/XMLSchema#string

J Watanabe

http://www.w3.org/2001/XMLSchema#string

K Miyasaka

http://www.w3.org/2001/XMLSchema#string

K Miyazaki

http://www.w3.org/2001/XMLSchema#string

K Sakakibara

http://www.w3.org/2001/XMLSchema#string

M Gondo

http://www.w3.org/2001/XMLSchema#string

M Kobayashi

http://www.w3.org/2001/XMLSchema#string

S Tamaoki

http://www.w3.org/2001/XMLSchema#string

S Tsukagoshi

http://www.w3.org/2001/XMLSchema#string

T Mikami

http://www.w3.org/2001/XMLSchema#string

P2860

Rhizoxin, a macrocyclic lactone antibiotic, as a new antitumor agent against human and murine tumor cells and their vincristine-resistant sublines

Antitumor activity of a new platinum complex, oxalato (trans-l-1,2-diaminocyclohexane)platinum (II): new experimental data.

A phase II study of Navelbine (vinorelbine) in the treatment of non-small-cell lung cancer.

Microtubule assembly in the absence of added nucleotides.

Natural products which interact with tubulin in the vinca domain: maytansine, rhizoxin, phomopsin A, dolastatins 10 and 15 and halichondrin B.

Multidrug-resistance phenotype in Chinese hamster ovary cells.

Role of P-glycoprotein in dolastatin 10 resistance.

New natural products under development at the National Cancer Institute.

Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia.

Dolastatin 15, a potent antimitotic depsipeptide derived from Dolabella auricularia. Interaction with tubulin and effects of cellular microtubules.

P304

316-327

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1349-7006.1997.TB00383.X

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

88

http://www.w3.org/2001/XMLSchema#string

P577

1997-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14078549

http://www.w3.org/2001/XMLSchema#string

P698

9140117

http://www.w3.org/2001/XMLSchema#string

P932

5921373

http://www.w3.org/2001/XMLSchema#string